Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2026)

Cytek Biosciences filings provide 6 years of Other Non-Current Liabilities readings, the most recent being $2.3 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 2.41% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a 2.41% decrease, with the full-year FY2025 number at $2.3 million, down 2.41% from a year prior.
  • Other Non-Current Liabilities hit $2.3 million in Q4 2025 for Cytek Biosciences, down from $2.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.5 million in Q3 2025 to a low of $737000.0 in Q3 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $1.9 million (2023), compared with a mean of $1.8 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 94.98% in 2022 and later decreased 12.13% in 2024.
  • Cytek Biosciences' Other Non-Current Liabilities stood at $1.2 million in 2021, then skyrocketed by 31.81% to $1.6 million in 2022, then soared by 53.18% to $2.4 million in 2023, then decreased by 2.76% to $2.4 million in 2024, then fell by 2.41% to $2.3 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.